Research findings, pricing news, and analysis on GLP-1 drugs and weight loss peptides.
New research from the Technical University of Munich and Harvard Medical School reveals that semaglutide and tirzepatide don't just promote weight loss — they appear to fundamentally reshape the body's metabolic and inflammatory pathways in ways researchers didn't fully anticipate.
Read more →New research from the University of Eastern Finland has found that semaglutide (Ozempic/Wegovy) is associated with significantly reduced rates of depression, anxiety, and substance use disorders — adding to a growing body of evidence that GLP-1 drugs do far more than cause weight loss.
Read more →The Trump administration announced deals with Eli Lilly and Novo Nordisk to significantly reduce the cost of weight loss medications through TrumpRx. Here's what we know and what it means for people taking semaglutide or tirzepatide.
Read more →